Fast track — ArticlesDose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry
Introduction
Between 0·3% and 0·7% of all pregnancies are in women with epilepsy.1 Most of these women need to continue use of antiepileptic drugs during pregnancy because uncontrolled seizures might harm the mother and fetus. This continuation is of concern to physicians, because antiepileptic drugs as a class might cause major congenital malformations2, 3 and adverse effects on cognitive development after prenatal exposure.4
In the past decade, the teratogenicity of antiepileptic drugs has been compared through large prospective registries.5 A recent systematic review3 concluded that “it is highly probable that intrauterine first-trimester exposure to valproic acid has a higher risk of major congenital malformations compared with carbamazepine, and possibly compared with phenytoin or lamotrigine”. Subsequent case-control studies have confirmed that, compared with other antiepileptic drugs, treatment with valproic acid has a greater risk of spina bifida, atrial septal defects, cleft palate, and craniosynostosis,6 and carbamazepine a greater risk of spina bifida.7 However, the associations reported in these observational studies could be influenced by confounders such as type or severity of epilepsy, socioeconomic status, and family history of birth defects. The findings of several studies also suggest an association between dose and risk of malformations, at least for valproic acid.8, 9, 10, 11, 12, 13 However, none of the previous studies had sufficient statistical power to compare risks associated with different doses of the most common drugs or to assess the influence of potential confounders. In this study, we aimed to assess data collected prospectively over 11 years by the International Registry of Antiepileptic Drugs and Pregnancy (EURAP)14 to establish the risks of major congenital malformations after monotherapy exposure to four major antiepileptic drugs at different doses.
Section snippets
Participants
The EURAP registry was established in 1999 and at present involves 42 countries with more than 700 collaborators. The eligibility criteria for prospective assessment in EURAP were treatment with antiepileptic drugs for any indication at conception, enrolment within gestation week 16, and enrolment before fetal outcome is known. Information is obtained in early pregnancy on demographics, type of epilepsy, seizure frequency, comorbidities, family history of major congenital malformations, drug
Results
For our present analysis, a cutoff date of June 9, 2010, was arbitrarily established, at which point 14 461 pregnancies had been registered. Of these pregnancies, we prospectively identified 5366 in which the women were exposed to antiepileptic monotherapy and had completed the 12-month follow-up (figure). 826 pregnancies were subsequently excluded (demographics listed webappendix pp 7–8), whereas 4540, representing 20 different antiepileptic drugs, fulfilled the eligibility criteria. These
Discussion
Our findings show that the risk of major congenital malformations increases dose-dependently with all assessed antiepileptic drugs. We recorded particularly high malformation rates for 1500 mg per day or greater doses of valproic acid. Doses of valproic acid of less than 700 mg per day were associated with a malformation rate in a similar range to that of carbamazepine doses of 400 mg per day to less than 1000 mg per day, phenobarbital of less than 150 mg per day, and lamotrigine of 300 mg per
References (34)
- et al.
Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts
Epilepsy Res
(2008) - et al.
Congenital malformations due to antiepileptic drugs
Epilepsy Res
(1999) - et al.
The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial
Lancet
(2007) - et al.
Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy
Epilepsia
(2006) - et al.
Management issues for women with epilepsy—focus on pregnancy (an evidence-based review)—II: Teratogenesis and perinatal outcomes
Epilepsia
(2009) - et al.
Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs
N Engl J Med
(2009) - et al.
Pregnancy registries: differences, similarities, and possible harmonization
Epilepsia
(2010) - et al.
Valproic acid monotherapy in pregnancy and major congenital malformations
N Engl J Med
(2010) - et al.
Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study
BMJ
(2010) - et al.
Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy
Epilepsia
(1997)
Antiepileptic drug regimens and major congenital abnormalities in the offspring
Ann Neurol
Antiepileptic drug use of women with epilepsy and congenital malformations in offspring
Neurology
Critical relationship between sodium valproate dose and the human teratogenicity: results of the Australian register of antiepileptic drugs in pregnancy
J Clin Neuroscience
Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register
J Neurol Neurosurg Psychiatry
Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry
Neurology
Proposal for revised classification of epilepsies and epilepstic syndromes
Epilepsia
EUROCAT guide 1.3 and reference documents: instructions for the registration and surveillance of congenital anomalies
Cited by (587)
Association of oxcarbazepine concentration with seizure frequency in pregnant women with epilepsy
2024, Epilepsy and Behavior ReportsEffects of valproic acid on syncytialization in human placental trophoblast cell lines
2023, Toxicology and Applied PharmacologyProposal for reference values for the developmental effects of valproate based on human data using a benchmark dose approach
2023, Regulatory Toxicology and PharmacologyAntiseizure Medications in Pregnancy
2023, Obstetrics and Gynecology Clinics of North America
- ‡
Group members listed at end of paper, with a complete list of collaborators given in the webappendix pp 1–6